Managing residual risk in patients receiving statin therapy

Ian R Hamilton-Craig
Med J Aust 2011; 194 (1): . || doi: 10.5694/j.1326-5377.2011.tb04160.x
Published online: 3 January 2011

In reply: In the interests of scientific exactitude, I am indebted to Marilyn Mann for corrections regarding the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. However, as the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial did not include the control group ezetimibe versus placebo, the effects of ezetimibe on carotid intima media thickness remain somewhat speculative.1

  • Ian R Hamilton-Craig

  • School of Medicine, Griffith University, Gold Coast, QLD.

Competing interests:

I have served on lipid advisory boards for Merck Sharp and Dohme, Solvay/Abbott and AstraZeneca, and have received speaker fees and reimbursement for travel/accommodation expenses to attend scientific meetings from these companies. I have also received honoraria from these companies and from Novartis, Pfizer, Schering Plough and Servier for presentations at postgraduate scientific meetings.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.